Stevanato Group S.p.A. (STVN) reported fourth‑quarter and full‑year 2025 results that exceeded analyst expectations, driven by strong demand for its high‑value drug delivery platforms and a favorable mix of high‑margin products.
Total revenue rose 5% to €346.5 million in Q4, up from €330.6 million in the same period a year earlier, and reached €1.186 billion for the year, matching the constant‑currency full‑year figure reported for 2024. The Biopharmaceutical and Diagnostic Solutions (BDS) segment generated €307.1 million, a 10% increase, while high‑value solutions accounted for €171.4 million, up 31% and representing 49% of total revenue.
Gross profit margin expanded to 30.9%, an increase of 120 basis points, and operating profit margin grew to 20.2%, up 70 basis points, reflecting the company’s successful shift toward higher‑margin products and improved vial market utilization. The margin gains offset the 23% decline in Engineering segment revenue, which fell to €39.5 million from €51.6 million a year earlier.
Net profit for the quarter was €47.6 million, giving diluted earnings per share of €0.17, a beat of €0.02 against the consensus estimate of €0.15. The EPS gain was driven by disciplined cost management and a favorable product mix that increased the contribution of high‑margin high‑value solutions.
Management guided for fiscal 2026 revenue of €1.26 billion to €1.29 billion, a range that is lower than the previously reported €1.467 billion to €1.500 billion, and adjusted EBITDA of €331.8 million to €346.9 million. CEO Franco Stevanato noted that GLP‑1 products accounted for 19% to 20% of revenue in 2025, that capacity at the Latina and Fishers facilities is near full utilization, and that the Engineering segment’s recovery will take longer than expected.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.